The phase-three clinical trial of the Oxford COVID-19 vaccine, Covishield, is being conducted by the SII.
According to The Indian Express, the SII has stated that data from four clinical studies shows that Covishield is highly effective against COVID-19 infections.
As per the Indian Council of Medical Research (ICMR), the SII has manufactured 40 million doses of the vaccine under the at-risk manufacturing and stockpiling license it obtained from the DCGI, reported PTI.
The firm stated that the results were in line with anti-coronavirus vaccines and that the Covishield vaccine is predicted to reduce COVID-19 mortality and morbidity.
“Therefore, Covishield is safe and well-tolerated and can be used effectively for prevention of COVID-19 in the targeted population. Thus, the benefit to risk ratio strongly supports the widespread use of Covishield,” PTI quoted a source as saying.
Serum Institute of India in Pune has also submitted 12 batches of the vaccine to the Central Drugs…
